A Phase 4 interventional study of Ranibizumab in Macular Edema, sponsored by Genentech, Inc.. Completed at 42 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-04-23.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 91 studies testing ranibizumab in Macular Edema — none open to participants now, none under way, none of them phase 3. Ranibizumab · Macular Edema.
Among the 91 studies testing ranibizumab in Macular Edema, this one is the 21st largest by enrollment, is one of 11 that started in 2011, is one of 26 in phase 4, and was the 27th registered.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
Browse Macular Edema studies →None of the 91 studies testing ranibizumab in Macular Edema is open now. The open studies under Macular Edema, anywhere →
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
91 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 28 · Phase 3 28 · Phase 4 26
First in 2004; this study’s year is marked. 11 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 202 is above the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 50 across the 91 interventional studies. Of the 65 that completed or were terminated, 39 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 91 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
28 studies in Macular Edema by Hoffmann-La Roche: 1 open now, 5 under way, 1 of them phase 3. Of 23 finished, 17 (74%) have results posted.
Among the 28 studies in Macular Edema by Hoffmann-La Roche, this one is the 18th largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2011, is one of 2 in phase 4, and was the 5th registered.
Hoffmann-La Roche’s Macular Edema studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 91 studies testing ranibizumab in Macular Edema, from their registry updates:
Among Hoffmann-La Roche’s 28 in Macular Edema:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a Phase IV multicenter, randomized, open-label study, with masking of the vision examiner, of the efficacy and safety of intravitreal ranibizumab 0.5 mg in subjects with macular edema following Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO).
This study consisted of 2 study periods, a 7-month fixed treatment period, followed by an 8-month alternate dose regimen period. Subjects could receive up to a maximum of 15 monthly injections of ranibizumab 0.5 mg during the study, 7 injections (Day 0 and at 6 monthly visits) in the fixed treatment period and a maximum of 8 injections in the alternate dose regimen period. During the fixed treatment period, subjects received 7 monthly intravitreal ranibizumab 0.5 mg injections. During the alternate dose regimen period, from Month 7 through Month 14, subjects were evaluated monthly to determine whether they achieved the study-specific visual acuity and spectral-domain optical coherence tomography (VA-OCT) stability criteria. Subjects continued to receive monthly ranibizumab 0.5 mg monthly injections until the VA-OCT stability criteria were first met. Upon meeting the VA-OCT stability criteria for the first time during the alternate dose regimen period, subjects were randomly assigned in a 1:1 ratio to one of 2 dose regimens, the PRN (pro re nata, "as-needed") or the Monthly regimen.
PRN randomized subjects: Subjects received no injection at the randomization visit and at future monthly visits where the VA-OCT stability criteria were met and received a ranibizumab 0.5 mg injection at future monthly visits if the VA-OCT stability criteria were not met.
Monthly randomized subjects: Subjects continued to receive ranibizumab 0.5 mg injections at each monthly visit.
Monthly non-randomized subjects: Subjects who did not meet the VA-OCT stability criteria at any month from Month 7 through Month 14 were not randomized and received 8 monthly intravitreal ranibizumab 0.5 mg injections.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Ocular Inclusion Criteria (Study Eye)
Exclusion Criteria:
Ocular Exclusion Criteria (Study Eye)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received at least 7 monthly intravitreal ranibizumab 0.5 mg injections until the first month where the study-specific visual acuity and spectral-domain optical coherence tomography (VA-OCT) stability criteria were met and randomization occurred to the monthly arm. At subsequent monthly visits after randomization, injections were given whether the VA-OCT stability criteria were met or not met. Subjects were to receive 15 ranibizumab 0.5 mg injections.
Drug: Ranibizumab
Subjects received at least 7 monthly intravitreal ranibizumab 0.5 mg injections until the first month where the study-specific VA-OCT stability criteria were met and randomization occurred to the PRN arm. No injection was given at the randomization visit. At subsequent monthly visits after randomization, injections were given if the VA-OCT stability criteria were not met and no injections were given if the VA-OCT stability criteria were met. Subjects could receive between 7 and a maximum of 14 ranibizumab 0.5 mg injections.
Drug: Ranibizumab
Subjects received at least 7 monthly intravitreal ranibizumab 0.5 mg injections and then never met the study-specific VA-OCT stability criteria from month 7 to month 14. Subjects were to receive 15 ranibizumab 0.5 mg injections.
Drug: Ranibizumab
Liquid ranibizumab (10 mg/ml) was supplied in a sterile solution in single-use vials.
Also known as: Lucentis
Trend of Change From Baseline in the Best Corrected Visual Acuity (BCVA) Scores From Month 7 to Month 15
BCVA was measured in the study eye using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision. A positive change score indicates improvement. The reported data are the observed changes from Baseline in BCVA at Months 7 and 15. For the statistical analysis, the interaction term of treatment by time in a longitudinal model was used to assess whether there was a difference in the trend of change from Baseline in the visual acuity scores from Month 7 to Month 15 between the 2 randomized treatment groups, Monthly and PRN.
Time frame: Baseline to Month 15
Visual Acuity Change From Previous Month During the Alternate Dose Regimen Period in Subjects Who Met the VA-OCT Stability Criteria at the Previous Month
BCVA was measured in the study eye using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision. A positive change score indicates improvement. This outcome measure is not relevant for subjects in the non-randomized group because they never met the VA-OCT stability criteria.
Time frame: Month 7 through Month 15
Percentage of Participants Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline
BCVA was measured in the study eye using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision.
Time frame: Month 7 to Month 15
Percentage of Participants With a Visual Acuity (VA) Snellen Equivalent of 20/40 or Better
VA was measured in the study eye using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart starting at a test distance of 4 meters. An increase in the number of lines read correctly by the patient in the ETDRS chart indicates an improvement of vision. The Snellen equivalent of 20/40 or better is 69 or more letters correctly read in the EDTRS chart.
Time frame: Month 7 to Month 15
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score
BCVA was measured in the study eye using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision. A positive change score indicates improvement.
Time frame: Month 1 to Month 15
Percentage of Participants Who Lost < 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline
BCVA was measured in the study eye using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision.
Time frame: Month 7 to Month 15
Percentage of Participants With a Central Foveal Thickness of ≤ 300 µm
Central foveal thickness was assessed monthly in the study eye using spectral-domain optical coherence tomography. Central foveal thickness was computed using the automated Cirrus Review software (DOCTR CZM Cirrus OCT Grader Reading Manual, Version 1.02). All participants in the Monthly and PRN groups had a baseline central foveal thickness \> 300 µm at baseline.
Time frame: Month 7 to Month 15
Mean Change From Baseline in Central Foveal Thickness
Central foveal thickness was assessed monthly in the study eye using spectral-domain optical coherence tomography. Central foveal thickness was computed using the automated Cirrus Review software (DOCTR CZM Cirrus OCT Grader Reading Manual, Version 1.02). All participants in the Monthly and PRN groups had a baseline central foveal thickness \> 300 µm at baseline. A decrease in foveal thickness suggests a reduction in macular edema. A negative change score indicates improvement.
Time frame: Month 1 to Month 15
Percentage of Participants With Intraretinal Edema
The presence of intraretinal edema was defined as the presence of subretinal fluid, cystoid spaces, or central retinal thickness ≥ 300 µm as evaluated in spectral-domain optical coherence tomography images by the Digital Angiography Reading Center, the central reading center. At baseline, all participants in the Monthly and PRN groups had presence of edema.
Time frame: Month 7 to Month 15
| Milestone | Ranibizumab 0.5 mg Monthly - Randomized Subjects | Ranibizumab 0.5 mg PRN - Randomized Subjects | Ranibizumab 0.5 mg Monthly - Non-randomized Subjects |
|---|---|---|---|
| Started | 85 | 86 | 31 |
| Completed | 85 | 86 | 19 |
| Not completed | 0 | 0 | 12 |
| Withdrew: Subject decision to withdraw | 0 | 0 | 8 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 |
| Withdrew: Subject required other drug therapy | 0 | 0 | 1 |
| Withdrew: Subject non-compliance | 0 | 0 | 1 |
| Milestone | Ranibizumab 0.5 mg Monthly - Randomized Subjects | Ranibizumab 0.5 mg PRN - Randomized Subjects | Ranibizumab 0.5 mg Monthly - Non-randomized Subjects |
|---|---|---|---|
| Started | 85 | 86 | 19 |
| Completed | 80 | 82 | 13 |
| Not completed | 5 | 4 | 6 |
| Withdrew: Death | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 3 |
| Withdrew: Subject decision to withdraw | 3 | 0 | 1 |
| Withdrew: Subject non-compliance | 0 | 2 | 1 |
| Withdrew: Relocation | 1 | 0 | 1 |
BCVA was measured in the study eye using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision. A positive change score indicates improvement. The reported data are the observed changes from Baseline in BCVA at Months 7 and 15. For the statistical analysis, the interaction term of treatment by time in a longitudinal model was used to assess whether there was a difference in the trend of change from Baseline in the visual acuity scores from Month 7 to Month 15 between the 2 randomized treatment groups, Monthly and PRN.
| Letters | Ranibizumab 0.5 mg Monthly - Randomized Subjects | Ranibizumab 0.5 mg PRN - Randomized Subjects |
|---|---|---|
| Month 7 (n=85, 86) | 17.5 ± 12.6 | 19.7 ± 12.6 |
| Month 15 (n=80, 82) | 18.7 ± 14.1 | 21.0 ± 14.1 |
BCVA was measured in the study eye using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision. A positive change score indicates improvement. This outcome measure is not relevant for subjects in the non-randomized group because they never met the VA-OCT stability criteria.
| Letters | Ranibizumab 0.5 mg Monthly - Randomized Subjects | Ranibizumab 0.5 mg PRN - Randomized Subjects |
|---|---|---|
| Month 8 (n=53, 53) | 0.4 ± 3.2 | -3.3 ± 11.3 |
| Month 9 (n=49, 40) | 0.5 ± 4.0 | -2.9 ± 8.6 |
| Month 10 (n=52, 31) | 0.2 ± 3.4 | -0.5 ± 4.2 |
| Month 11 (n=54, 40) | -0.6 ± 3.7 | 0.4 ± 4.4 |
| Month 12 (n=46, 44) | -0.2 ± 3.2 | -1.6 ± 4.4 |
| Month 13 (n=50, 41) | 0.0 ± 3.5 | -0.5 ± 5.2 |
| Month 14 (n=58, 48) | -0.1 ± 3.6 | -2.2 ± 6.1 |
| Month 15 (n=56, 42) | 0.0 ± 4.4 | -0.4 ± 4.0 |
BCVA was measured in the study eye using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision.
| Percentage of participants | Ranibizumab 0.5 mg Monthly - Randomized Subjects | Ranibizumab 0.5 mg PRN - Randomized Subjects | Ranibizumab 0.5 mg Monthly - Non-randomized Subjects |
|---|---|---|---|
| Month 7 (n=85, 86, 17) | 62.4 (52.1 to 72.7) | 67.4 (57.5 to 77.3) | 41.2 (17.8 to 64.6) |
| Month 15 (n=80, 82, 13) | 66.3 (55.9 to 76.6) | 70.7 (60.9 to 80.6) | 46.2 (19.1 to 73.3) |
VA was measured in the study eye using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart starting at a test distance of 4 meters. An increase in the number of lines read correctly by the patient in the ETDRS chart indicates an improvement of vision. The Snellen equivalent of 20/40 or better is 69 or more letters correctly read in the EDTRS chart.
| Percentage of participants | Ranibizumab 0.5 mg Monthly - Randomized Subjects | Ranibizumab 0.5 mg PRN - Randomized Subjects | Ranibizumab 0.5 mg Monthly - Non-randomized Subjects |
|---|---|---|---|
| Month 7 (n=85, 86, 17) | 72.9 (63.5 to 82.4) | 76.7 (67.8 to 85.7) | 47.1 (23.3 to 70.8) |
| Month 15 (n=80, 82, 13) | 71.3 (61.3 to 81.2) | 76.8 (67.7 to 86.0) | 46.2 (19.1 to 73.3) |
BCVA was measured in the study eye using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision. A positive change score indicates improvement.
| Letters | Ranibizumab 0.5 mg Monthly - Randomized Subjects | Ranibizumab 0.5 mg PRN - Randomized Subjects | Ranibizumab 0.5 mg Monthly - Non-randomized Subjects |
|---|---|---|---|
| Month 1 (n=85, 86, 29) | 12.2 ± 10.3 | 11.2 ± 10.4 | 10.7 ± 14.0 |
| Month 7 (n=85, 86, 17) | 17.5 ± 12.6 | 19.7 ± 12.6 | 14.7 ± 12.0 |
| Month 15 (n=80, 82, 13) | 18.7 ± 14.1 | 21.0 ± 14.1 | 14.5 ± 14.7 |
BCVA was measured in the study eye using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision.
| Percentage of participants | Ranibizumab 0.5 mg Monthly - Randomized Subjects | Ranibizumab 0.5 mg PRN - Randomized Subjects | Ranibizumab 0.5 mg Monthly - Non-randomized Subjects |
|---|---|---|---|
| Month 7 (n=85, 86, 17) | 98.8 (96.5 to 100.0) | 98.8 (96.6 to 100.0) | 100.0 (NA to NA) |
| Month 15 (n=80, 82, 13) | 98.8 (96.3 to 100.0) | 98.8 (96.4 to 100.0) | 100.0 (NA to NA) |
Central foveal thickness was assessed monthly in the study eye using spectral-domain optical coherence tomography. Central foveal thickness was computed using the automated Cirrus Review software (DOCTR CZM Cirrus OCT Grader Reading Manual, Version 1.02). All participants in the Monthly and PRN groups had a baseline central foveal thickness \> 300 µm at baseline.
| Percentage of participants | Ranibizumab 0.5 mg Monthly - Randomized Subjects | Ranibizumab 0.5 mg PRN - Randomized Subjects | Ranibizumab 0.5 mg Monthly - Non-randomized Subjects |
|---|---|---|---|
| Month 7 (n=85, 86, 17) | 88.2 (81.4 to 95.1) | 94.2 (89.2 to 99.1) | 52.9 (29.2 to 76.7) |
| Month 15 (n=80, 82, 13) | 92.5 (86.7 to 98.3) | 85.4 (77.7 to 93.0) | 38.5 (12.0 to 64.9) |
Central foveal thickness was assessed monthly in the study eye using spectral-domain optical coherence tomography. Central foveal thickness was computed using the automated Cirrus Review software (DOCTR CZM Cirrus OCT Grader Reading Manual, Version 1.02). All participants in the Monthly and PRN groups had a baseline central foveal thickness \> 300 µm at baseline. A decrease in foveal thickness suggests a reduction in macular edema. A negative change score indicates improvement.
| µm | Ranibizumab 0.5 mg Monthly - Randomized Subjects | Ranibizumab 0.5 mg PRN - Randomized Subjects | Ranibizumab 0.5 mg Monthly - Non-randomized Subjects |
|---|---|---|---|
| Month 1 (n=85, 86, 29) | -243.0 ± 172.5 | -214.9 ± 166.7 | -157.9 ± 181.8 |
| Month 7 (n=85, 86, 17) | -279.7 ± 167.4 | -265.2 ± 185.9 | -113.9 ± 184.9 |
| Month 15 (n=80, 82, 13) | -289.9 ± 177.2 | -247.8 ± 207.5 | -93.2 ± 225.2 |
The presence of intraretinal edema was defined as the presence of subretinal fluid, cystoid spaces, or central retinal thickness ≥ 300 µm as evaluated in spectral-domain optical coherence tomography images by the Digital Angiography Reading Center, the central reading center. At baseline, all participants in the Monthly and PRN groups had presence of edema.
| Percentage of participants | Ranibizumab 0.5 mg Monthly - Randomized Subjects | Ranibizumab 0.5 mg PRN - Randomized Subjects | Ranibizumab 0.5 mg Monthly - Non-randomized Subjects |
|---|---|---|---|
| Month 7 (n=85, 86, 17) | 31.8 (21.9 to 41.7) | 30.2 (20.5 to 39.9) | 100.0 (NA to NA) |
| Month 15 (n=80, 82, 13) | 25.0 (15.5 to 34.5) | 32.9 (22.8 to 43.1) | 84.6 (65.0 to 100.0) |
Collected over Adverse Events were reported beginning at initiation of study treatment up to 30 days following the last administration of study treatment, study discontinuation, or termination, whichever was earlier.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranibizumab 0.5 mg Monthly - Randomized Subjects | — | 12/85 (14.1%) | 70/85 (82.4%) |
| Ranibizumab 0.5 mg PRN - Randomized Subjects | — | 14/86 (16.3%) | 61/86 (70.9%) |
| Ranibizumab 0.5 mg Monthly - Non-randomized Subjects | — | 11/31 (35.5%) | 18/31 (58.1%) |
| Event | Ranibizumab 0.5 mg Monthly - Randomized Subjects | Ranibizumab 0.5 mg PRN - Randomized Subjects | Ranibizumab 0.5 mg Monthly - Non-randomized Subjects |
|---|---|---|---|
| Visual acuity reducedEye disorders | 1/85 | 3/86 | 0/31 |
| Coronary artery diseaseCardiac disorders | 0/85 | 0/86 | 1/31 |
| DeathGeneral disorders | 0/85 | 0/86 | 1/31 |
| DiverticulitisInfections and infestations | 0/85 | 0/86 | 1/31 |
| Neck injuryInjury, poisoning and procedural complications | 0/85 | 0/86 | 1/31 |
| Back painMusculoskeletal and connective tissue disorders | 0/85 | 0/86 | 1/31 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/85 | 0/86 | 1/31 |
| Pathological fractureMusculoskeletal and connective tissue disorders | 0/85 | 0/86 | 1/31 |
| Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/85 | 0/86 | 1/31 |
| Lung cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/85 | 0/86 | 1/31 |
| Event | Ranibizumab 0.5 mg Monthly - Randomized Subjects | Ranibizumab 0.5 mg PRN - Randomized Subjects | Ranibizumab 0.5 mg Monthly - Non-randomized Subjects |
|---|---|---|---|
| Conjunctival haemorrhageEye disorders | 28/85 | 23/86 | 9/31 |
| Eye painEye disorders | 8/85 | 14/86 | 4/31 |
| HypertensionVascular disorders | 13/85 | 8/86 | 2/31 |
| Retinal exudatesEye disorders | 13/85 | 12/86 | 3/31 |
| Vitreous detachmentEye disorders | 11/85 | 6/86 | 3/31 |
| NasopharyngitisInfections and infestations | 10/85 | 7/86 | 1/31 |
| CataractEye disorders | 9/85 | 6/86 | 0/31 |
| Macular fibrosisEye disorders | 9/85 | 5/86 | 2/31 |
| Upper respiratory tract infectionInfections and infestations | 3/85 | 3/86 | 3/31 |
| Vitreous adhesionsEye disorders | 0/85 | 0/86 | 3/31 |
Intent-to-treat population: All enrolled participants who received at least 1 ranibizumab injection in the study.
| Age, Continuous(years) | Ranibizumab 0.5 mg Monthly - Randomized Subjects | Ranibizumab 0.5 mg PRN - Randomized Subjects | Ranibizumab 0.5 mg Monthly - Non-randomized Subjects | Total |
|---|---|---|---|---|
| Mean | 67.3 ± 12.1 | 65.2 ± 12.8 | 66.3 ± 12.3 | 66.3 ± 12.4 |
| Sex: Female, Male(Participants) | Ranibizumab 0.5 mg Monthly - Randomized Subjects | Ranibizumab 0.5 mg PRN - Randomized Subjects | Ranibizumab 0.5 mg Monthly - Non-randomized Subjects | Total |
|---|---|---|---|---|
| Female | 38 | 37 | 9 | 84 |
| Male | 47 | 49 | 22 | 118 |
The record gives a start of Feb 2011, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2014, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab